A61K 2239/49
Breast
A61K2239/49 (Breast) appears on 226 US grants and 518 published applications in this corpus.
Search patents in A61K- Granted patents
- 226
- Published applications
- 518
- Assignees
- 277
- Inventors
- 1,019
- Latest grant
- 15 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2000 | 1 | 0 |
| 2001 | 1 | 0 |
| 2002 | 2 | 7 |
| 2003 | 3 | 6 |
| 2004 | 2 | 7 |
| 2005 | 1 | 5 |
| 2006 | 1 | 6 |
| 2007 | 0 | 3 |
| 2008 | 3 | 12 |
| 2009 | 3 | 10 |
| 2010 | 4 | 5 |
| 2011 | 5 | 9 |
| 2012 | 4 | 7 |
| 2013 | 1 | 10 |
| 2014 | 6 | 13 |
| 2015 | 12 | 11 |
| 2016 | 10 | 15 |
| 2017 | 6 | 23 |
| 2018 | 12 | 26 |
| 2019 | 5 | 27 |
| 2020 | 15 | 47 |
| 2021 | 9 | 42 |
| 2022 | 17 | 49 |
| 2023 | 28 | 49 |
| 2024 | 25 | 53 |
| 2025 | 31 | 39 |
| 2026 | 19 | 37 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Anti-MUC1-C antibodies and CAR-T structures15 Sep 2026US 12,735,503 B2TeneoBio, Inc.
- Anti-MUC1 compositions and methods of use21 Jul 2026US 12,686,726 B2Poseida Therapeutics, Inc.
- Polypeptide specific for mucin 1 and use thereof23 Jun 2026US 12,661,402 B2LG Chem.Ltd.
- Compositions and methods of enhancing immunotherapies9 Jun 2026US 12,648,927 B2Cha Therapeutics, Inc.
- Armed dual CAR-T compositions and methods for cancer immunotherapy2 Jun 2026US 12,643,933 B2Simcere Innovation, Inc.
- Compositions and methods for delivery of immune cells to treat un-resectable or non-resected tumor cells and tumor relapse8 Oct 2026US 2026/0308532 A1Fred Hutchinson Cancer Center
- T-cell receptors targeting her2 and methods of use thereof1 Oct 2026US 2026/0297158 A1Board of Regents, The University of Texas System
- Chimeric antigen receptors and their derivatives and applications17 Sep 2026US 2026/0272980 A1Fudan University
- Enhanced Expansion of Tumor-Infiltrating Lymphocytes for Adoptive Cell Therapy3 Sep 2026US 2026/0258358 A1Board of Regents, The University of Texas System
- Bi-specific adapters and their use with universal car-t cells in the treatment of tumors and the inhibition of cancer-associated fibroblasts27 Aug 2026US 2026/0248923 A1Purdue Research Foundation
Most cited
By later US patents
- Activation and expansion of T-cells using an engineered multivalent signaling platform as a research tool110US 8,637,307 B2The Trustees of the University of Pennsylvania · 2014
- Compositions, methods, and computer systems related to making and administering modified T cells107US 9,499,855 B2Elwha LLC · 2016
- Cancer immunotherapy using tumor cells combined with mixed lymphocytes81US 6,207,147 B1The Regents of the University of California · 2001
- Gene expression analysis of pluri-differentiated mesenchymal progenitor cells and methods for diagnosing a leukemic disease state81US 7,049,072 B2University of South Florida · 2006
- Activation and expansion of T-cells using an engineered multivalent signaling platform as a research tool81US 7,745,140 B2The Trustees of the University of Pennsylvania · 2010